Ascension Life Fund celebrates its first exit with the acquisition of Aparito by Eli Lilly, reflecting a strategic and successful investment in innovative health tech solutions.

Information on the Target

Ascension Life Fund celebrates its first exit with the acquisition of Aparito by Eli Lilly and Company. Aparito is an innovative company that is transforming the clinical trials landscape by enabling remote monitoring through disease-specific smartphone applications, video assessments, and wearable technology. Their focus on conducting trials in patients' homes allows for the collection of electronic clinical outcome assessments (eCOAs) and digital biomarkers, enhancing efficiency and patient engagement.

This acquisition occurs merely six months after Ascension's initial investment, signifying a substantial rise in the company's valuation and highlighting Aparito's potential in revolutionizing healthcare solutions.

Industry Overview in the UK

The UK healthcare sector is in the midst of a significant transformation, driven by advancements in technology and a push for more patient-centric care. With an increasing demand for efficiency and accessibility in healthcare